Immune Thrombocytopenic Purpura (ITP)Symptoms, Doctors, Treatments, Advances & More
Learn About Immune Thrombocytopenic Purpura (ITP)
Condition 101 content is not available at this time, but we are continually updating the site. Please check back.
However, there may be experts who have treated this or similar conditions in our Find a Doctor section and research may be available in our Latest Advances section.
University Of Penn - Medical Group
Adam Cuker is a Hematologist practicing medicine in Philadelphia, Pennsylvania. Dr. Cuker is rated as an Elite provider by MediFind in the treatment of Immune Thrombocytopenic Purpura (ITP). He is also highly rated in 27 other conditions, according to our data. His clinical expertise encompasses Thrombocytopenia, Immune Thrombocytopenic Purpura (ITP), Adult Immune Thrombocytopenia, Splenectomy, and Knee Replacement.
Ballad Health Cancer Center
Asheesh Shipstone is a Hematologist and an Oncologist practicing medicine in Kingsport, Tennessee. Dr. Shipstone is rated as an Advanced provider by MediFind in the treatment of Immune Thrombocytopenic Purpura (ITP). He is also highly rated in 54 other conditions, according to our data. His clinical expertise encompasses Adult Immune Thrombocytopenia, Colorectal Cancer, Hemangioma Thrombocytopenia Syndrome, and Thrombocytopenia. Dr. Shipstone is board certified in American Board Of Internal Medicine.
Vince Lombardi Cancer Clinic
Adam Siegel is a Hematologist and an Oncologist practicing medicine in Summit, Wisconsin. Dr. Siegel is rated as an Advanced provider by MediFind in the treatment of Immune Thrombocytopenic Purpura (ITP). He is also highly rated in 46 other conditions, according to our data. His clinical expertise encompasses Adult T-Cell Leukemia, Chronic T-Cell Leukemia (CTCL), Angiosarcoma, and Inflammatory Breast Cancer. Dr. Siegel is board certified in American Board Of Internal Medicine, Hematology.
Summary: This is a Phase 2, open-label, multicenter, multiple subcutaneous injection, safety and efficacy study of PF-06835375 in adult participants with primary immune thrombocytopenia (ITP). This study will focus on participants with persistent (\>3 months and ≤12 months), or chronic (\>12 months) ITP
Summary: The purpose of this study is to determine if a dose dense administration of Rituximab in newly diagnosed acute immune thrombocytopenic purpura (ITP) and determine relapse rate following this treatment. Correlative studies will be performed as outlined in the appendices. Quality of Life will be measured using the KIT as outlined in the protocol.